Targets › IL22
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Cytokine that plays a critical role in modulating tissue responses during inflammation. Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage. (UniProt, Q9GZX6)
Open in Phaseline: the race on IL22, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | CP-IL22BP mRNA IL-22 binding protein (IL-22BP) delivered via cationic peptide; IL-22 axis inhibitor | IL22 | Phase 1 | mRNA Vaccine | Jun 2027 |
| Xingchen Peng | IL-22BP/LNP compound IL-22BP mRNA vaccine | IL22 | Phase 1 | Refractory Malignant Solid Tumors | – |
mRNA Vaccine (1) Refractory Malignant Solid Tumors (1)
other (2)
West China Hospital (1) Xingchen Peng (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.